Study Shows Positive Results for mRNA-Based Combination Influenza and COVID-19 Vaccine
A Phase I/II study evaluating the safety, tolerability and immunogenicity of Pfizer and BioNTech’s mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age show positive topline results.
Intranasal COVID-19 Vaccine Shows High Seroresponse
A Phase I randomized, double-blind, placebo-controlled dose-escalation study in healthy adults, called CDX-CoV-001, has found Codagenix’s intranasal COVID-19 vaccine candidate, CoviLiv, showed the vaccine had a high seroresponse rate and induced mucosal immunity in volunteers not previously vaccinated or infected.
Moderna’s Influenza-COVID-19 Vaccine Demonstrates Immunogenecity
Results from Moderna’s Phase I/II clinical trial that evaluated the safety and immunogenicity of its influenza-COVID-19 vaccine, mRNA 1083, showed immunogenicity against all four influenza strains compared to a standard dose of the influenza vaccine, Fluarix, in adults 50 to 64 years of age and against an enhanced influenza vaccine, Fluzone HD, in adults 65 to 79 years of age.
HHS Forms the Office of Long COVID Research and Practice and Launch of Long COVID Clinical Trials
The U.S. Department of Health and Human Services has founded the Office of Long COVID Research and Practice to lead the Long COVID response and coordination across the federal government. In addition, the National Institutes of Health launched Long COVID clinical trials through the RECOVER Initiative.
Personalized Digital Care Program Improves Outcomes in Long COVID and Autoimmune Disease
According to data, patients with autoimmune diseases or long COVID who used a personalized digital care program (DCP) developed by Mymee alongside other nonpharmacologic strategies were more likely to achieve better health-related quality of life scores.
HHS Issues Amendment to PREP Act for Medical Countermeasures Against COVID-19
The U.S. Department of Health and Human Services (HHS) has issued an amendment to the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19.
FDA Retires Monovalent COVID-19 Vaccines
The U.S. Food and Drug Administration has amended the emergency use authorizations of the. Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals.
COVID-19 Year Three: How Medical Professionals Can Balance Life, Family and Practice
Is finding a healthy work-life balance possible in the post-pandemic world?
New Test Identifies Patients at Risk of Severe COVID-19
U.S. scientists have developed a new genomic test that can predict a patient’s risk of developing severe COVID-19, an advance that could help doctors quickly begin tailored treatment.
Combination COVID-19 and Influenza Vaccine Under Development
Despite technical challenges, some companies are working on making a combination COVID and flu vaccine.